CHINA Bio-Immunity Corporation (CHHB) has announced an update regarding the nationwide recall of its rabies vaccines.
13/03/2009
Merck intends to expand its research and development (R&D) presence in China by making it the company's fourth key R&D hub for Merck Serono division worldwide. Merck plans to invest more than 150 million Euros.
24/11/2009
CLINICAL Data have announced its Cogenics division has partnered with SinoGenoMax expanding its clinical genotyping service to the growing market in China.
21/01/2009
BAYER Schering Pharma has announced they will invest 100m Euro ($A197m) into the development of a global research and development centre in Beijing, China.
14/02/2009
AVEXA has been awarded a grant under round eight of the Australia-China Special Fund for Science and Technology Cooperation in support of its joint drug-discovery projects with Shanghai Company, TargetDrug.
07/04/2009
PERKINELMER has announced it has completed the acquisition of Shanghai-based SYM-BIO Lifescience, a leading provider of diagnostics instruments and related reagents.
09/09/2009
BAYER Technology Services has officially opened its first regional office in India in an effort enlarge its presence in the growing Asian markets.
13/03/2009
VARIAN Medical Systems has announced it will showcase its full range of cancer treatment and X-ray imaging products at theChina Med 21st International Medical Instruments and Equipment Exhibition in Bejing on 19 to 21 March 2009
18/03/2009
BAYER HealthCare, Onyx Pharmaceuticals and Roche have announced the initiation of the Phase III trail examining Nexavar (sorafenib) tablets in combination with Tarceva (erlotinib) tablets as a potential treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.
29/05/2009
Merck has begun a Phase III study of the therapeutic cancer vaccine Stimuvax (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The study will investigate if Stimuvax can extend overall survival in Asian patients with unresectable stage III NSCLC.
14/12/2009
Australian researchers are members of an international consortium entering a new era of personalised medicine for cancer patients.
03/05/2010